Literature DB >> 27172994

Protein S is protective in pulmonary fibrosis.

M Urawa1,2, T Kobayashi1, C N D'Alessandro-Gabazza2, H Fujimoto1, M Toda2, Z Roeen2, J A Hinneh2, T Yasuma2, Y Takei1,3, O Taguchi1, E C Gabazza2.   

Abstract

UNLABELLED: Essentials Epithelial cell apoptosis is critical in the pathogenesis of idiopathic pulmonary fibrosis. Protein S, a circulating anticoagulant, inhibited apoptosis of lung epithelial cells. Overexpression of protein S in lung cells reduced bleomycin-induced pulmonary fibrosis. Intranasal therapy with exogenous protein S ameliorated bleomycin-induced pulmonary fibrosis.
SUMMARY: Background Pulmonary fibrosis is the terminal stage of interstitial lung diseases, some of them being incurable and of unknown etiology. Apoptosis plays a critical role in lung fibrogenesis. Protein S is a plasma anticoagulant with potent antiapoptotic activity. The role of protein S in pulmonary fibrosis is unknown. Objectives To evaluate the clinical relevance of protein S and its protective role in pulmonary fibrosis. Methods and Results The circulating level of protein S was measured in patients with pulmonary fibrosis and controls by the use of enzyme immunoassays. Pulmonary fibrosis was induced with bleomycin in transgenic mice overexpressing human protein S and wild-type mice, and exogenous protein S or vehicle was administered to wild-type mice; fibrosis was then compared in both models. Patients with pulmonary fibrosis had reduced circulating levels of protein S as compared with controls. Inflammatory changes, the levels of profibrotic cytokines, fibrosis score, hydroxyproline content in the lungs and oxygen desaturation were significantly reduced in protein S-transgenic mice as compared with wild-type mice. Wild-type mice treated with exogenous protein S showed significant decreases in the levels of inflammatory and profibrotic markers and fibrosis in the lungs as compared with untreated control mice. After bleomycin infusion, mice overexpressing human protein S showed significantly low caspase-3 activity, enhanced expression of antiapoptotic molecules and enhanced Akt and Axl kinase phosphorylation as compared with wild-type counterparts. Protein S also inhibited apoptosis of alveolar epithelial cells in vitro. Conclusions These observations suggest clinical relevance and a protective role of protein S in pulmonary fibrosis.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  anticoagulants; apoptosis; coagulation; lung fibrosis; protein S

Mesh:

Substances:

Year:  2016        PMID: 27172994     DOI: 10.1111/jth.13362

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Reply to D'Alessandro-Gabazza et al.: Risks of Treating Idiopathic Pulmonary Fibrosis with a TAM Receptor Kinase Inhibitor.

Authors:  Milena S Espindola; David M Habiel; Cory M Hogaboam
Journal:  Am J Respir Crit Care Med       Date:  2018-10-01       Impact factor: 21.405

2.  A cellular census of human lungs identifies novel cell states in health and in asthma.

Authors:  Felipe A Vieira Braga; Gozde Kar; Marijn Berg; Orestes A Carpaij; Krzysztof Polanski; Lukas M Simon; Sharon Brouwer; Tomás Gomes; Laura Hesse; Jian Jiang; Eirini S Fasouli; Mirjana Efremova; Roser Vento-Tormo; Carlos Talavera-López; Marnix R Jonker; Karen Affleck; Subarna Palit; Paulina M Strzelecka; Helen V Firth; Krishnaa T Mahbubani; Ana Cvejic; Kerstin B Meyer; Kourosh Saeb-Parsy; Marjan Luinge; Corry-Anke Brandsma; Wim Timens; Ilias Angelidis; Maximilian Strunz; Gerard H Koppelman; Antoon J van Oosterhout; Herbert B Schiller; Fabian J Theis; Maarten van den Berge; Martijn C Nawijn; Sarah A Teichmann
Journal:  Nat Med       Date:  2019-06-17       Impact factor: 53.440

3.  Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis.

Authors:  A Tomaru; T Kobayashi; J A Hinneh; P Baffour Tonto; C N D'Alessandro-Gabazza; H Fujimoto; K Fujiwara; Y Takahashi; M Ohnishi; T Yasuma; K Nishihama; M Yoshino; K Takao; M Toda; T Totoki; Y Takei; K Yoshikawa; O Taguchi; E C Gabazza
Journal:  Gene Ther       Date:  2017-08-18       Impact factor: 5.250

Review 4.  Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis.

Authors:  Mattia Bellan; Micol Giulia Cittone; Stelvio Tonello; Cristina Rigamonti; Luigi Mario Castello; Francesco Gavelli; Mario Pirisi; Pier Paolo Sainaghi
Journal:  Int J Mol Sci       Date:  2019-10-12       Impact factor: 5.923

Review 5.  Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy.

Authors:  Aurelia Magdalena Pisoschi; Aneta Pop; Florin Iordache; Loredana Stanca; Ovidiu Ionut Geicu; Liviu Bilteanu; Andreea Iren Serban
Journal:  Eur J Med Chem       Date:  2022-02-04       Impact factor: 6.514

6.  Renal Injury during Long-Term Crizotinib Therapy.

Authors:  Taro Yasuma; Tetsu Kobayashi; Corina N D'Alessandro-Gabazza; Hajime Fujimoto; Kentaro Ito; Yoichi Nishii; Kota Nishihama; Prince Baffour Tonto; Atsuro Takeshita; Masaaki Toda; Esteban C Gabazza; Osamu Taguchi; Shigenori Yonemura; Osamu Hataji
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923

7.  Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Score-Matched Cohort Study.

Authors:  Marcin Protasiewicz; Konrad Reszka; Wojciech Kosowski; Barbara Adamik; Wojciech Bombala; Adrian Doroszko; Damian Gajecki; Jakub Gawryś; Maciej Guziński; Maria Jedrzejczyk; Krzysztof Kaliszewski; Katarzyna Kilis-Pstrusinska; Bogusława Konopska; Agnieszka Kopec; Krzysztof Kujawa; Anna Langner; Anna Larysz; Weronika Lis; Lilla Pawlik-Sobecka; Joanna Gorka-Dynysiewicz; Marta Rosiek-Biegus; Agnieszka Matera-Witkiewicz; Tomasz Matys; Michał Pomorski; Mateusz Sokolski; Janusz Sokołowski; Anna Tomasiewicz-Zapolska; Katarzyna Madziarska; Ewa A Jankowska
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

8.  Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis.

Authors:  Mark R Jackson; Katrina Stevenson; Sandeep K Chahal; Emer Curley; George E Finney; Rodrigo Gutierrez-Quintana; Evarest Onwubiko; Angie Rupp; Karen Strathdee; Karin Williams; Megan K L MacLeod; Charles McSharry; Anthony J Chalmers
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-31       Impact factor: 7.038

9.  Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis.

Authors:  Corina N D'Alessandro-Gabazza; Taro Yasuma; Tetsu Kobayashi; Masaaki Toda; Ahmed M Abdel-Hamid; Hajime Fujimoto; Osamu Hataji; Hiroki Nakahara; Atsuro Takeshita; Kota Nishihama; Tomohito Okano; Haruko Saiki; Yuko Okano; Atsushi Tomaru; Valeria Fridman D'Alessandro; Miyako Shiraishi; Akira Mizoguchi; Ryoichi Ono; Junpei Ohtsuka; Masayuki Fukumura; Tetsuya Nosaka; Xuenan Mi; Diwakar Shukla; Kensuke Kataoka; Yasuhiro Kondoh; Masaki Hirose; Toru Arai; Yoshikazu Inoue; Yutaka Yano; Roderick I Mackie; Isaac Cann; Esteban C Gabazza
Journal:  Nat Commun       Date:  2022-03-23       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.